XENICAL (orlistat) EFECTOS SECUNDARIOS !!!
XENICAL (orlistat) ADVERSE EFFECTS !!!
Efectos secundarios de la molécula XENICAL (orlistat) utilizada
para bajar de peso, la cual no es muy buena, que te puede matar, que
produce daño hepático, pancreático, cáncer, depresión y lesiones de
piel, desordenes gastrointestinales, hipertensión y otras mas,
altamente cuestionada hoy en día.
EFECTOS ADVERSOS DESCRITOS
- Cambios en los hábitos de evacuación de los intestinos
- Aumento en las deposiciones
- Deposiciones incontrolables
- Heces grasas o aceitosas
- Heces blandas
- Manchas aceitosas en la ropa interior
- Muerte
- Necrosis hepática masiva
- Pancreatitis
- Cancer
- Depresión
- Lesiones cutáneas
XENICAL (orlistat) asociado a muerte, (Referencia 7)....
".... 99 casos de pancreatitis asociadas a orlistat reportó la FDA.....solo."
Saludos a Todos.
Dr. José Lapenta.
Dr. José M. Lapenta.
ENGLISH EDITORIAL
================
Side effects of the XENICAL (orlistat) molecule used to lose weight,
which is not very good, that can kill you, that produces hepatic and
pancreatic damage, cancer, depression and skin lesions, hypertension and
gastrointestinal disorders, highly questioned nowaday.
ADVERSE EFFECTS
1. Changes in bowel movement habits
2. Increase in bowel movements
3. uncontrollable bowel movements
4. Greasy or oily stools
5. loose stools
6. Oily stains on underwear
7. Death
8. massive liver necrosis
9. pancreatitis
10. Cáncer
11.Depression
12 skin lesions
XENICAL (orlistat) people have killed, (reference 7).
"......99 cases of orlistat related pancreatitis have been reported to the Food and Drug Administration..."
Greetings to all
Dr. José Lapenta
Dr. José M. Lapenta
=================================================================
REFERENCIAS BIBLIOGRAFICAS/ BIBLIOGRAPHICAL REFERENCES
=================================================================
1.)
Severe hepatic injury caused by orlistat.
2.) Obesity Drug Xenical
Should be Banned: Public Citizen.
3.) 36 year old man presenting with
pancreatitis and a history of recent commencement of Orlistat case
report.
4.) The anti-obesity agent Orlistat is associated to increase
in colonic preneoplastic markers in rats treated with a chemical
carcinogen.
5.) Constipation, polyuria, polydipsia, and edema
associated with orlistat.
6.) [A case of acute cholestatic hepatitis
associated with Orlistat][Article in Korean].
7.) Massive
hepatocellular [correction of hepatocullular] necrosis: was it caused by
Orlistat?.
8.) Additive gastrointestinal effects with concomitant use
of olestra and orlistat.
9.) Bulimia nervosa and misuse of orlistat:
two case reports.
10.) Lichenoid eruption associated with
orlistat.
11.) Orlistat (Xenical)-induced subacute liver failure.
12.)
Orlistat Side Effects.
13.) Public Citizen renews call for FDA to ban
both prescription and over-the counter distribution of Xenical (Orlistat)
- 6/7/06.
=================================================================
Source:
Umemura T, Ichijo T, Matsumoto A, Kiyosawa K.
PMID:
16887401 [PubMed - indexed for MEDLINE]
2.) Obesity Drug Xenical Should be Banned:
Source:
Public CitizenThe prescription obesity drug Xenical (orlistat) should be immediately removed from the U.S. market because it may increase the risk of aberrant crypt foci (ACF), which are widely believed to be a precursor to colon cancer, the consumer advocacy group Public Citizen said in a petition filed Monday with the Food and Drug Administration.
Public Citizen, based in Washington, D.C., said its petition is
based on findings from a review of data from Roche Pharmaceuticals, which
makes orlistat, and recent findings that the drug causes ACF in the colon
of rats.
The group also expressed concern that the FDA seems
poised to approve U.S. sales of an over-the-counter version of
orlistat.
"The failure to ban the prescription version of this
drug or worse, to make it much more widely available by allowing OTC
sales, is a decision that is likely to increase cancer incidence," Dr.
Sidney Wolfe, director of Public Citizen's Health Research Group, said in
a prepared statement.
Joining Public Citizen in the petition
are Case Western Reserve School of Medicine pathologists -- Dr. Theresa
Pretlow and Dr. Thomas Pretlow -- who are experts on ACF's link to
colorectal cancer.
3.) 36 year old man presenting with pancreatitis and a history of recent commencement of Orlistat case report.Napier S, Thomas M.Nutr J. 2006 Aug 28;5:19.
Source:
Bristol Royal Infirmary, Marlborough Street, Bristol, BS2 8HW,
UK. sarahjnapier@yahoo.co.uk
BACKGROUND: Orlistat is an
anti-obesity drug licensed in the United Kingdom for 7 years. We present a
case of a patient who developed pancreatitis four days after commencing
orlistat. CASE PRESENTATION: A 36 year old man presented to hospital with
acute severe pancreatitis four days after starting a course of Orlistat, a
lipase inhibitor used in the treatment of obesity. A diagnosis of drug
related pancreatitis was made by exclusion of other causes of
pancreatitis; he was a teetotaller, had a normal serum calcium, had no
family history of pancreatitis or hyperlipidaemia, no history of trauma
and had no evidence of gallstones on Computerised Tomography scan (CT).
CONCLUSION: Orlistat was the only drug that had been started recently and
has been associated with pancreatitis previously. We found no case reports
of similar cases, however 99 cases of orlistat related pancreatitis have
been reported to the Food and Drug Administration (FDA), but no causative
link has been found in clinical trials by the drug company. It is
therefore not on the list of possible complications or side effects of the
drug.
PMID: 16938137 [PubMed - indexed for MEDLINE]
4.) The anti-obesity agent Orlistat is associated to increase in
colonic preneoplastic markers in rats treated with a chemical
carcinogen.
Source:
Cancer Lett. 2006 Aug 28;240(2):221-4. Epub 2005 Dec 27
Garcia
SB,
Barros LT,
Turatti A,
Martinello F,
Modiano P,
Ribeiro-Silva
A,
Vespucio MV,
Uyemura SA.
Department of Pathology,
Ribeirao Preto Medical School, University of Sao Paulo, USP, Avenida
Bandeirantes 3900, 14049-900 Ribeirao Preto, SP,
Brazil. sbgarcia@fmrp.usp.br
Orlistat is an anti-obesity
agent that increases the fecal fat excretion, which promotes colon
carcinogenesis. Therefore, the present study was designed to verify the
effects of Orlistat on the formation of rat colonic aberrant crypt foci
(ACF) and cell proliferation evaluated by the PCNA method. Male Wistar
rats received either a standard diet or a high fat diet (HFD),
supplemented or not with Orlistat (200mg/kg chow) and two doses of the
carcinogen dimethyl-hydrazine (25mg/Kg). After 30 days, Orlistat was
associated to a significant increase in the number of colonic ACFs and
cell proliferation in DMH-treated animals, independently of the HFD.
PMID:
16377080 [PubMed - indexed for MEDLINE]
5.) Constipation, polyuria, polydipsia, and edema associated with
orlistat.
Source:
Packard KA, Wurdeman Ann Pharmacother. 2002
Jul-Aug;36(7-8):1168-70.
RL, Reyes AP.
Creighton Cardiac
Center, Omaha, NE 68131-2044, USA. kelliot@cardiac.creighton.edu
OBJECTIVE:
To report the occurrence of a novel group of adverse effects associated
with initiation and rechallenge of orlistat. CASE SUMMARY: A 42-year-old
white woman developed symptoms of constipation, polyuria, polydipsia, and
increased lower-leg edema after 2 weeks of treatment with orlistat 120 mg
3 times daily. The drug was discontinued for 4 days and the symptoms
resolved. On reinstitution of the orlistat treatment, the symptoms
reappeared within 2 days. Thereafter, the medication was permanently
discontinued. DISCUSSION: Common gastrointestinal adverse reactions
associated with orlistat use include fecal urgency and abdominal pain and
discomfort. Pedal edema has also been reported to occur, although less
frequently. No reports were discovered documenting the occurrence of
constipation, polydipsia, and polyuria associated with the use of
orlistat. Despite careful consideration of other possible causes of these
symptoms, the temporal association between initiation, discontinuation,
and rechallenge of orlistat and the patient's symptoms suggest a
medication-related adverse event. Based on the Naranjo probability scale,
the likelihood that orlistat was the cause of this cluster of adverse
effects is possible. CONCLUSIONS: It is important for the healthcare
provider to be aware of these adverse effects to promptly evaluate and
differentiate between possible causes of similar reactions.
6.) [A case of acute cholestatic hepatitis associated with
Orlistat][Article in Korean]
Source:
Taehan Kan Hakhoe Chi. 2002 Sep;8(3):317-20.
Kim DH, Lee EH,
Hwang JC, Jeung JH, Kim do H, Cheong JY, Cho SW, Kim YB.
Department
of Gastroenterology, Ajou University College of Medicine, Suwon, Korea.
Orlistat(Xenical(R),
Roche) is considered a safe and effective drug to treat obesity by reduced
absorption of 30% digested fat. To date, no serious adverse effects
affecting the liver have been published except a case of subacute hepatic
failure leading to liver transplantation in a young women with moderate
obesity treated with orlistat. We report a case of acute cholestatic
hepatitis in a young woman with moderate obesity treated with orlistat: a
33-year-old female admitted for the evaluation of jaundice. Abdominal
ultrasonography, ERCP, routine chemistry, viral markers, and a fine needle
biopsy of liver were performed. Microscopic findings of the liver biopsy
specimen were compatible with acute cholestatic hepatitis. After steroid
therapy, liver function was improved.
PMID: 12499790 [PubMed -
indexed for MEDLINE]
7.) Massive hepatocellular [correction of hepatocullular] necrosis: was
it caused by Orlistat?
Source:
Lau G, Chan CL.
Med Sci Law. 2002 Oct;42(4):309-12.
Health
Sciences Authority, Centre for Forensic Medicine, Singapore, Republic of
Singapore. Gilbert_LAU@HSA.GOV.SG
Orlistat
(tetrahydrolipostatin) is a lipase inhibitor which is used, in conjunction
with appropriate dietary control, for the treatment of obesity. It is
generally deemed to be a safe drug, which mainly exerts a topical action
on the stomach and small bowel, with negligible systemic absorption and
oral bioavailability. Consequently, its adverse effects have largely been
limited to relatively mild gastrointestinal disorders. However, there have
been recent, published reports of non-fatal acute hepatitis and systemic
hypertension associated with its use. The present case concerns a
62-year-old male who died from massive hepatocellular necrosis, consistent
with drug-induced, fulminant hepatitis, associated with the use of oral
orlistat, presumably administered at the recommended daily dose of 360 mg.
It is postulated that this may represent a rare idiosyncratic reaction to
the drug.
PMID: 12487515 [PubMed - indexed for MEDLINE]
8.) Additive gastrointestinal effects with concomitant use of olestra
and orlistat.
Source:
Ann Pharmacother. 2002 Jun;36(6):1003-5.
Heck AM, Calis KA, McDuffie
JR, Carobene SE, Yanovski JA.
Purdue University School of Pharmacy
and Pharmacal Sciences, Indianapolis, IN 46202-2879,
USA. amheck@iupui.edu
OBJECTIVE: To report a case of
significant additive gastrointestinal effects with concomitant use of
orlistat and an olestra-containing snack food. CASE SUMMARY: A 16-year-old
African American girl with type 2 diabetes, hypercholesterolemia, and
hypertension was participating in a pilot study that tested the safety and
efficacy of orlistat. After 2 weeks of orlistat treatment, the patient
presented to the clinic with complaints of soft, fatty/oily stools, flatus
with discharge, abdominal pain, increased flatus, and fecal incontinence.
On further questioning, it was determined that she was also consuming
approximately 5 ounces of olestra-containing potato chips on a daily
basis. The patient eliminated olestra from her diet and returned to the
clinic with substantially diminished gastrointestinal adverse effects,
despite continuing to take orlistat. DISCUSSION: This is the first
published case describing additive gastrointestinal effects after
concurrent use of orlistat and olestra. Education about the potential for
serious additive gastrointestinal adverse effects is important to prevent
premature and unnecessary discontinuation of orlistat therapy. Awareness
of this potential interaction could be especially important for patients
with underlying disease states in which severe gastrointestinal symptoms
could result in significant complications. CONCLUSIONS: This case
illustrates that significant gastrointestinal distress may result after
olestra consumption during orlistat therapy. All patients receiving
orlistat for the management of obesity should be properly educated about
this potential drug-food interaction.
PMID: 12022901 [PubMed -
indexed for MEDLINE]
9.) Bulimia nervosa and misuse of orlistat: two case reports.
Source:
Fernandez-Aranda F, Amor A, Jimenez-Murcia S, Gimenez-Martinez L,
Int
J Eat Disord. 2001 Dec;30(4):458-61.
Turon-Gil V,Vallejo-Ruiloba
J.
Department of Psychiatry, University Hospital of Bellvitge,
Barcelona, Spain. ffernandez@csub.scs.es
OBJECTIVE:
Orlistat (tetrahydrolipstatin) is an intestinal lipase inhibitor that was
approved recently for the management and treatment of obesity. This is the
first report of the misuse of orlistat in two normal-weight purging
bulimia nervosa (BN) patients. METHOD AND RESULTS We report two diagnosed
cases of BN in two Spanish women who used orlistat as a purging mechanism
after binge episodes. In both cases, the onset of the eating disorder was
in adolescence. From the beginning, a restrictive diet, binging, and
purging behavior (vomiting and using laxatives) were present. Both
patients misused this substance as their only purging mechanism after
every binge episode. CONCLUSION: BN patients have used many substances and
bizarre behaviors as purging mechanisms. Nevertheless, to the authors'
knowledge, these are the first reported cases of orlistat misuse as the
only purging mechanism in two BN patients. Copyright 2001 by John Wiley
& Sons, Inc.
10.) Lichenoid eruption associated with orlistat.
Source:
Br J Dermatol. 2006 May;154(5):1020-1. Links
PMID: 16634924 [PubMed
- indexed for MEDLINE]
11.) Orlistat (Xenical)-induced subacute liver failure.
Source:
Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1437-8.
Thurairajah
PH, Syn WK, Neil DA, Stell D, Haydon G.
PMID: 16292105 [PubMed
- indexed for MEDLINE]
Related Links[A case of acute cholestatic hepatitis associated with Orlistat]
[Taehan Kan Hakhoe Chi. 2002] PMID: 12499790
Depression induced by orlistat (Xenical) [Can J Psychiatry. 2000]
PMID: 10696499 Orlistat associated subacute hepatic failure. [J Hepatol. 2001]
PMID: 11211898 Over-the-counter orlistat. A weight loss "Alli" or adversary on the
horizon. [AWHONN Lifelines. 2006] PMID: 17069574
[Is xenical hepatotoxic?] [Gastroenterol Clin Biol. 2000] PMID: 10804353
12.) Orlistat Side Effects
Source:
Orlistat (also referred to as Xenical) is a lipase-inhibitor drug
designed by Hoffman La-Roche Laboratories to help obese individuals lose
and maintain their body weight. The drug works by preventing fat from
being absorbed by the body but can cause excess gas, oily discharge and
other gastrointestinal problems. Although this may sound like a miracle
weight loss drug, it has hidden cancer risks which are emerging that
clearly outweigh any possible benefit the drug may have. According to
research studies, people who use it have a higher risk of developing both
colon cancer and breast cancer.
Have you or someone you know
suffered from Orlistat Side Effects? Contact us for a free consultation on
your potential case against Orlistat Side Effects today!
Colon
cancer concerns have spurred the consumer advocate group, Public Citizen,
to petition the FDA asking it to withdraw the prescription diet drug from
the market; the group also wants the FDA to refuse approval for the
weight-loss pill to be made widely available over the counter. Public
Citizen has a strong track record of identifying dangerous drugs well
before federal regulators take action to ban or put warnings on these
drugs. For example, Public Citizen warned consumers about the dangers of
Vioxx, Ephedra, Bextra, Rezulin, Baycol, Propulsid and many other drugs
years before the drugs were pulled from the market. Public Citizen,
representing over 100,000 consumers in this petition, has moved forward
with the petition based on research that shows people taking Orlistat have
a significant risk of developing aberrant crypt foci. Aberrant crypt foci
has been found to be a precursor to colon cancer.
Orlistat side
effects has also been determined to be associated with higher risks of
developing breast cancer. According to research data submitted by Hoffman
La-Roche in its application to the FDA requesting approval, that it has a
higher risk of developing breast cancer. Data from Hoffman La-Roche’s
clinical studies showed that It accelerated the development of breast
cancer in women over 45 years of age or older when given the medication
orally at a dose of 120 milligrams three times per day. This data
initially gave the FDA concern and it held off on approving the drug. In
the seven randomized, controlled clinical trials, there were 10 cases of
breast cancer in the treated group with only one in the control group. The
relative risk of getting breast cancer while taking Orlistat (compared to
those taking a placebo) was calculated several times by both the FDA and
the sponsor and found to vary between 4 and 7 fold, depending on the
analysis. These results caused the FDA Medical Officer to rescind his
original approval. However, the FDA recommended that the warning labels
contain information related to this risk, also asked for post marketing
surveys be conducted. No such warnings were included in the products
labels, and to the present date no post marketing surveys have been
performed.
Have you or someone you know suffered from Orlistat
Side Effects? Contact us for a free consultation on your potential case
against Orlistat Side Effects today!
13.) Public Citizen renews call for FDA to ban both prescription and
over-the counter distribution of Xenical (Orlistat) - 6/7/06
Source: Public Citizen
In a letter published in the Cancer
Letter, a weekly newsletter that publishes news and items related to
cancer research, the consumer group Public Citizen renewed its call upon
the acting commissioner of the FDA to ban both prescription and
over-the-counter distribution of orlistat. Xenical is the prescription
version of orlistat, an obesity-fighting drug which Roche Laboratories and
GlaxoSmithKline hope to sell over-the-counter to the public. GSK announced
on April 7 that it had learned the FDA would soon approve its
over-the-counter version of orlistat, to be called Alli, once the company
answered some remaining questions. If approved, Alli would be the first
over-the-counter version of orlistat. The FDA has still not granted Alli
full approval for sale in the U.S.
Orlistat has been found to
cause a marked increase in the incidence of aberrant intestinal crypts, or
crypt foci, widely believed to be a precursor of colon cancer. These
aberrant crypt foci, or ACF, are considered pre-cancerous changes; lesions
that serve as "biomarkers" or signs of cancer growing in the body.
Public
Citizen testified before an FDA advisory panel on January 23rd to oppose
the approval of orlistat for over-the-counter sales. Four researchers on
the panel who were subsequently interviewed by the Cancer Letter were not
informed at or prior to the January 23rd meeting about the studies that
found orlistat induced ACF in animal colons, an outcome Public Citizen
said is documented in two studies.
University of Chicago
gastroenterologist Marc Bissonnette, a panel researcher, said in the June
5 Public Citizen statement that the FDA’s apparent decision not to
consult researchers on the ACF question appears consistent with the recent
failures by the FDA to detect dangers in the toxicity of drugs. "It
reminds me of the Vioxx story, unfortunately, and lots of other stories
like it," Bissonnette said.
Sources: Ed Silverman, "Advocacy
group objects to weight-loss drug," New Jersey Star-Ledger, June 6, 2006,
accessed June 7, 2007; Sidney M. Wolfe, MD; Elizabeth Barbehenn, PhD;
Peter Lurie, MD, MPH; "Supplement to petition to ban diet drug orlistat
(XENICAL). Additional information provided about pre-cancerous changes to
the colon (HRG Publication #1771)," Public Citizen, June 5, 2006, accessed
June 7, 2006.
=============================================================
Producido Por Dr. Jose Lapenta R. Dermatologo
Maracay Estado Aragua Venezuela 2.007-2.023
Telf: 04142976087- 04127766810
04166401045
Follow @dermagicexpress
Producido Por Dr. Jose Lapenta R. Dermatologo
Maracay Estado Aragua Venezuela 2.007-2.023
Telf: 04142976087- 04127766810
04166401045
Follow @dermagicexpress